PredictCan Biotechnologies owns a unique cell educating technology that allows us to generate patient-centric physiologically relevant in vitro models (GenuineSelect) suitable for high throughput screen (HTS). We have developed a patient-centric HCC model that demonstrated a high quality of prediction of clinical outcomes, a determining parameter for phenotypic drug discovery.

Lead compounds could be identified by compound library screening on cohort of patient-centric HCC models prior to target deconvolution and compounds’ optimization.

Target and efficacy are validated on independent cohorts of patient-centric HCC models.